Until recently, the only systemic regimen known to impact overall survival (OS) in men with
symptomatic metastatic castration-resistant prostate cancer (mCRPC) was a taxane-based …

Simple Summary Prostate cancer is the second most common cancer in males. In prostate
cancer cells, androgens bind and activate the intracellular mediator called Androgen …

Androgens play a critical role in the progression of castration-resistant prostate cancer
through androgen receptor (AR)-regulated signaling pathways. Progress has been made in …

Castrate resistant prostate cancer (CRPC) remains a disease with significant morbidity and
mortality. The recent approval of abiraterone and enzalutamide highlight the improvements …

The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in
prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth …

In the castration-resistant state, androgen receptor (AR)-signaling remains a critical driver of
prostate cancer cell growth. This realization led to the development of the next-generation …

Recent advances in understanding the mechanisms underlying the development and
progression of castration resistant prostate cancer from androgen-sensitive prostate cancer …

Prostate cancer (PCa) is a hormone-sensitive disease. Androgen deprivation therapy lowers
serum testosterone levels (castration) or blocks the androgen receptor (AR) ligand-binding …

Purpose: Galeterone inhibits the enzyme CYP17A1 and is currently in phase II clinical trials
for castration-resistant prostate cancer (CRPC). Galeterone is also a direct androgen …

Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-
resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is …